Review ArticlesPulmonary Artery Denervation as an Innovative Treatment for Pulmonary Hypertension With and Without Heart FailureKim, Chan W. MS; Aronow, Wilbert S. MD; Dutta, Tanya MD; Spevack, Daniel M. MD; Frishman, William H. MDAuthor Information From the Department of Medicine, Cardiology Division, Westchester Medical Center and New York Medical College, Valhalla, NY. Disclosure: The authors declare no conflict of interest. Correspondence: Wilbert S. Aronow, MD, FACC, FAHA, Professor of Medicine and Director of Cardiology Research, Cardiology Division, Westchester Medical Center, Macy Pavilion, Room 141, Valhalla, NY 10595. E-mail: [email protected]. Cardiology in Review: March/April 2021 - Volume 29 - Issue 2 - p 89-95 doi: 10.1097/CRD.0000000000000299 Buy Metrics Abstract Pulmonary hypertension (PH) is categorized into 5 groups based on etiology. The 2 most prevalent forms are pulmonary arterial hypertension (PAH) and PH due to left heart disease (PH-LHD). Therapeutic options do exist for PAH to decrease symptoms and improve functional capacity; however, the mortality rate remains high and clinical improvements are limited. PH-LHD is the most common cause of PH; however, no treatment exists and the use of PAH-therapies is discouraged. Pulmonary artery denervation (PADN) is an innovative catheter-based ablation technique targeting the afferent and efferent fibers of a baroreceptor reflex in the main pulmonary artery (PA) trunk and its bifurcation. This reflex is involved in the elevation of the PA pressure seen in PH. Since 2013, both animal trials and human trials have shown the efficacy of PADN in improving PAH, including improved hemodynamic parameters, increased functional capacity, decreased PA remodeling, and much more. PADN has been shown to decrease the rate of rehospitalization, PH-related complications, and death, and is an overall safe procedure. PADN has also been shown to be effective for PH-LHD. Additional therapeutic mechanisms and benefits of PADN are discussed along with new PADN techniques. PADN has shown efficacy and safety as a potential treatment option for PH. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.